Erich Koller
Department of Molecular and Cellular Pharmacology
Isis Pharmaceuticals
Carlsbad
CA 92008
USA
Name/email consistency: high
- Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. Koller, E., Propp, S., Zhang, H., Zhao, C., Xiao, X., Chang, M., Hirsch, S.A., Shepard, P.J., Koo, S., Murphy, C., Glazer, R.I., Dean, N.M. Cancer Res. (2006)
- Competition for RISC binding predicts in vitro potency of siRNA. Koller, E., Propp, S., Murray, H., Lima, W., Bhat, B., Prakash, T.P., Allerson, C.R., Swayze, E.E., Marcusson, E.G., Dean, N.M. Nucleic Acids Res. (2006)
- Elucidating cell signaling mechanisms using antisense technology. Koller, E., Gaarde, W.A., Monia, B.P. Trends Pharmacol. Sci. (2000)









